Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.

ABSTRACT:

Background

Colorectal cancer is one of the most frequent neoplasms worldwide, and the majority of patients are diagnosed in advanced stages. Metastatic colorectal cancer (mCRC) harbors several mutations with different prognostic and predictive values; KRAS, NRAS, and BRAF mutations are the best known. Indeed, RAS and BRAF molecular status are associated with a different response to monoclonal antibodies (Anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor agents), which are usually added to chemotherapy in first-line, and thus allow to select the optimal therapy for patients with mCRC. Furthermore, sidedness is an important predictive and prognostic factor in mCRC, which is explained by the different molecula

SUBMITTER: Motta R 

PROVIDER: S-EPMC8710355 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature